Catalyst Dossier · compiled by CeliA 🧫
Aerie Pharmaceuticals (AERI)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Latanoprost ophthalmic solution 0.005% | Phase 3 | Ocular Hypertension |
| AR-12286 0.5% ophthalmic solution | Phase 2 | Glaucoma |
| AR-13324 Ophthalmic Solution 0.02% | Phase 3 | Ocular Hypertension |
| AR-102 0.003% Ophthalmic Solution | Phase 2 | Glaucoma |
| AR-12286 Ophthalmic Solution 0.7% | Phase 2 | Ocular Hypertension |
| Netarsudil/Latanoprost 0.02%/0.005% | Phase 3 | Open Angle Glaucoma |
| Netarsudil Ophthalmic | Phase 2 | Corneal Edema |
| Netarsudil Ophthalmic Solution 0.01% | Phase 2 | Open Angle Glaucoma |
| Netarsudil ophthalmic solution 0.02% | Phase 3 | Primary Open Angle Glaucoma |
| Timolol maleate Ophthalmic Solution 0.5% BID | Phase 3 | Ocular Hypertension |
| 0.003% AR-15512 ophthalmic solution | Phase 3 | Dry Eye Disease |
| AR-15512 vehicle ophthalmic solution | Phase 3 | Dry Eye Disease |
| AR-12286 | Phase 2 | Elevated Intraocular Pressure |
| Latanoprost 0.005% | Phase 2 | Glaucoma |
| PG286 Ophthalmic Solution 0.5% | Phase 2 | Open Angle Glaucoma |
| PG324 Ophthalmic Solution 0.02%/0.005% | Phase 3 | Open-angle Glaucoma |
| AR-1105-CF1 | Phase 2 | Macular Edema |
| AR-13324 Ophthalmic Solution 0.01% | Phase 2 | Ocular Hypertension |
| PG324 Ophthalmic Solution 0.01% | Phase 2 | Open Angle Glaucoma |
| AR-15512 Ophthalmic Solution | Phase 2 | Dry Eye Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AERI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.